Laboratorios Farmaceuticos ROVI (ROVI) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.116x

Based on the latest financial reports, Laboratorios Farmaceuticos ROVI (ROVI) has a cash flow conversion efficiency ratio of 0.116x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€73.37 Million ≈ $85.78 Million USD) by net assets (€632.80 Million ≈ $739.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ROVI equity to assets ratio to measure how much of total assets are equity-financed.

Laboratorios Farmaceuticos ROVI - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Laboratorios Farmaceuticos ROVI's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Laboratorios Farmaceuticos ROVI cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Laboratorios Farmaceuticos ROVI Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Laboratorios Farmaceuticos ROVI ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
nLIGHT Inc NASDAQ:LASR	0.077x
Palomar Holdings Inc NASDAQ:PLMR	0.095x
PROTECTOR FORSIKR.(ADS)/2 F:PR40	N/A
Abercrombie & Fitch Company NYSE:ANF	0.216x
Sims Ltd AU:SGM	0.062x
Uni-President China Holdings Ltd F:58U	0.031x
Genworth Financial Inc NYSE:GNW	0.009x
CIE Automotive S.A. MC:CIE	0.329x

Annual Cash Flow Conversion Efficiency for Laboratorios Farmaceuticos ROVI (2006–2024)

The table below shows the annual cash flow conversion efficiency of Laboratorios Farmaceuticos ROVI from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Laboratorios Farmaceuticos ROVI worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€581.54 Million ≈ $679.88 Million	€138.28 Million ≈ $161.66 Million	0.238x	+14.11%
2023-12-31	€543.49 Million ≈ $635.40 Million	€113.25 Million ≈ $132.40 Million	0.208x	-54.28%
2022-12-31	€521.38 Million ≈ $609.55 Million	€237.60 Million ≈ $277.78 Million	0.456x	+43.62%
2021-12-31	€470.98 Million ≈ $550.62 Million	€149.44 Million ≈ $174.71 Million	0.317x	+152.96%
2020-12-31	€373.70 Million ≈ $436.89 Million	€46.88 Million ≈ $54.80 Million	0.125x	+547.14%
2019-12-31	€322.39 Million ≈ $376.90 Million	€-9.04 Million ≈ $-10.57 Million	-0.028x	-194.53%
2018-12-31	€287.47 Million ≈ $336.08 Million	€8.53 Million ≈ $9.97 Million	0.030x	-68.47%
2017-12-31	€191.69 Million ≈ $224.10 Million	€18.04 Million ≈ $21.09 Million	0.094x	-62.09%
2016-12-31	€183.41 Million ≈ $214.42 Million	€45.53 Million ≈ $53.22 Million	0.248x	+39.17%
2015-12-31	€164.78 Million ≈ $192.65 Million	€29.39 Million ≈ $34.36 Million	0.178x	+22.88%
2014-12-31	€158.47 Million ≈ $185.27 Million	€23.00 Million ≈ $26.89 Million	0.145x	-29.67%
2013-12-31	€144.46 Million ≈ $168.89 Million	€29.82 Million ≈ $34.86 Million	0.206x	+33.06%
2012-12-31	€126.45 Million ≈ $147.83 Million	€19.61 Million ≈ $22.93 Million	0.155x	+39.39%
2011-12-31	€113.98 Million ≈ $133.26 Million	€12.68 Million ≈ $14.83 Million	0.111x	-45.31%
2010-12-31	€104.13 Million ≈ $121.74 Million	€21.19 Million ≈ $24.77 Million	0.203x	+51.20%
2009-12-31	€71.50 Million ≈ $83.59 Million	€9.62 Million ≈ $11.25 Million	0.135x	-48.51%
2008-12-31	€48.44 Million ≈ $56.63 Million	€12.66 Million ≈ $14.80 Million	0.261x	+1079.12%
2007-12-31	€51.92 Million ≈ $60.70 Million	€1.15 Million ≈ $1.35 Million	0.022x	-92.59%
2006-12-31	€25.81 Million ≈ $30.17 Million	€7.72 Million ≈ $9.02 Million	0.299x	--

About Laboratorios Farmaceuticos ROVI

MC:ROVI Spain Drug Manufacturers - Specialty & Generic

Market Cap

$3.50 Billion

€2.99 Billion EUR

Market Cap Rank

#4421 Global

#37 in Spain

Share Price

€58.55

Change (1 day)

-1.18%

52-Week Range

€52.00 - €85.55

All Time High

€90.54